February 24, 2021 — Occlutech announced the completion of patient enrollment in the PRELIEVE trial, pilot study to assess safety and efficacy of the novel Atrial Flow Regulator (AFR) in heart failure (HF) patients.
PRELIEVE is a prospective, multicenter, open-label, non-randomized pilot study that evaluates the results of AFR implantation in patients with either heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF).
